Select Your Region

Hemos detectado que accedes a esta página desde United States Selecciona tu región preferida para continuar.

Ir a United States (English)
ir al contenido

Selector de país

Según su ubicación

Europe

North America

Latin America

Asia-Pacific

Verificación del sector sanitario

Esta sección contiene información destinada a los profesionales sanitarios.

Confirme que pertenece a una empresa del sector sanitario.

Multiple Myeloma: « 20 » and « 100 » Ratios Cut-off applicable to Sebia FLC assays

The « 20 » and « 100 » Ratios Cut-off are respectively used in routine for high-risk smoldering multiple myeloma stratification and for assessing progression to active multiple myeloma or amyloidosis. This publication shows that such cut-off are applicable to the Sebia FLC assays.

Publicado: 10/11/2026 | Modificado: 10/11/2026

In 2014, the IMWG has added SLiM criteria (bone marrow plasmacytosis ≥ 60%, FLC i/u ≥100 along with the iFLC ≥ 100 mg/L, > 1 focal lesion on MRI) to the CRAB criteria (calcium elevation, renal insufficiency, anemia), as Myeloma Defining Events.

The iFLCr threshold (100) was defined because it was the cut-off associated with a 79% risk of progression to MM (Multiple Myeloma) or AL (AL amyloidosis) within 24 months, and with a specificity of 97% (Larsen JT et al, Leukemia, 2013).

In addition to this 100 ratio, the IMWG has then introduced the 20-20-20 system for assessing the Smoldering Multiple Myeloma (SMM) to MM progression. In that system, a patient with SMM receives 1 risk point for each of the following (M-spike>20 g/L, iFLCr>20 and BMPC>20%). This score is notably used for trial stratification and eligibility.

This publication indicates that the FLC cut-points can be used with Sebia ELISA FLC tests and allow for comparability within the field, to ensure an appropriate patient management.

Comparison-of-two-FLC_Publication

Test associated with this resource

Related instrument

Discover more resources on Multiple Myeloma

Esta sección contiene información destinada a una amplia difusión y, por lo tanto, puede incluir detalles de productos o información que no esté disponible o no sea válida en su país. Póngase en contacto con su representante local de Sebia. Información destinada a profesionales sanitarios. Lea atentamente las instrucciones que figuran en los prospectos de los reactivos y en los manuales de los instrumentos.

Multiple Myeloma Risk Stratification with FLC Ratio Cut-Offs | Sebia